Trial · NCT04589143
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
NCT04589143, Phase 4, Completed, Central South University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine. Trials, record NCT04589143. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04589143
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
- NCT number
- NCT04589143
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 137 participants, actual
- Lead sponsor
- Central South University
- Conditions
- Major Depressive Disorder
- Interventions
- Agomelatine, Placebos
- First posted
- 2020-10-19
- Last updated
- 2024-04-01
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hamilton Depression Scale scores | Baseline (week 0), week 2, week 4, week 8 | Depression severity; higher scores mean a worse outcome. |
| Primary | Side Effect Rating Scale (SERS) scores | Baseline (week 0), week 2, week 4, week 8 | Safety: frequency and severity of adverse events; higher scores mean a better outcome. |
| Secondary | Patient Health Questionnaire (PHQ-9) scores | Baseline (week 0), week 2, week 4, week 8 | Self-report depression severity; higher scores mean a worse outcome. |
| Secondary | Hamilton Anxiety Rating Scale (HAMA) scores | Baseline (week 0), week 2, week 4, week 8 | Anxiety severity; higher scores mean a worse outcome. |
| Secondary | General Anxiety Disorder-7 (GAD-7) scores | Baseline (week 0), week 2, week 4, week 8 | Self-report anxiety severity; higher scores mean a worse outcome. |
| Secondary | Changes in Clinical Global Impression (CGI) scores | Baseline (week 0), week 2, week 4, week 8 | Symptom severity; higher scores mean a worse outcome. |
| Secondary | Snaith-Hamilton Pleasure Scale (SHAPS) scores | Baseline (week 0), week 2, week 4, week 8 | Self-reported severity of anhedonia; higher scores mean a worse outcome. |
| Secondary | Sheehan Disability Scale (SDS) scores | Baseline (week 0), week 2, week 4, week 8 | Self-report tool that assesses functional impairment in work/school, social life, and family life; higher scores mean a worse outcome. |
| Secondary | Quality of life (EQ-5D-3L) scores | Baseline (week 0), week 2, week 4, week 8 | Self-report Quality of life; higher scores mean a better outcome. |
| Secondary | performance of Neurocognitive test, including executive function, attention, processing speed, and memory | Baseline (week 0), week 2, week 4, week 8 | Neurocognitive function; higher scores mean a better outcome. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40038707 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04589143
GET https://conductscience.org/api/trials/v1/NCT04589143/registered